# Neointimal Coverage After Implantation of Biolimus Eluting Stent With Biodegradable Polymer: Optical Coherence Tomographic Assessment According to the Treatment of Dyslipidemia and Hypertension and the Types of Implanted Drug-eluting Stents

> **NCT01502904** · PHASE4 · COMPLETED · sponsor: **Yonsei University** · enrollment: 120 (actual)

## Conditions studied

- Stable Angina or Acute Coronary Syndrome Considered for Percutaneous Coronary Intervention With Dyslipidemia or Hypertension

## Interventions

- **DEVICE:** Sirolimus-eluting stent
- **DEVICE:** Biolimus-eluting stents
- **DRUG:** pravastatin 20mg/day after DES implantation
- **DRUG:** pitavastatin 2mg/day after DES implantation
- **DRUG:** Non-ARB /day after DES implantation
- **DRUG:** Eposartan 600mg/day after DES implantation

## Key facts

- **NCT ID:** NCT01502904
- **Lead sponsor:** Yonsei University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07
- **Primary completion:** 2015-05
- **Final completion:** 2015-06
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2016-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01502904

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01502904, "Neointimal Coverage After Implantation of Biolimus Eluting Stent With Biodegradable Polymer: Optical Coherence Tomographic Assessment According to the Treatment of Dyslipidemia and Hypertension and the Types of Implanted Drug-eluting Stents". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01502904. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*